An interventional study of Platelet rich fibrin and Emdogain in Peridontal Disease and Furcation Defects, sponsored by Medical University of Sofia. Completed at 1 site in Bulgaria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by Medical University of Sofia · Not applicable, Interventional, and Treatment
This study evaluated the regenerative potential of platelet-rich fibrin (PRF) compared with enamel matrix derivative (Emdogain®) in the surgical treatment of Class II (F2) furcation defects of mandibular molars. Twenty-one systemically healthy patients with a total of 30 mandibular molars presenting with buccal Class II furcation defects were included. The furcation defects were treated surgically with either PRF or Emdogain®. Clinical parameters, including periodontal probing depth, clinical attachment level, bleeding on probing, and furcation involvement, were assessed before treatment and during follow-up. Clinical and radiographic measurements of the furcation defects were also performed. The main follow-up evaluation was conducted 6 months after surgery. The study compared the clinical and radiographic outcomes of PRF and Emdogain® in the treatment of mandibular molars with Class II furcation defects.
42 studies on the registry are indexed under Furcation Defects; 13 are open to participants now.
This study's enrollment of 21 is below the median of 27 across 38 interventional studies indexed under Furcation Defects.
Browse Furcation Defects studies →Medical University of Sofia is the lead sponsor of 12 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Surgical treatment of a mandibular molar with a Class II (F2) furcation defect using platelet-rich fibrin (PRF) following surgical debridement and root surface instrumentation.
Biological: Platelet rich fibrin
Surgical treatment of a mandibular molar with a Class II (F2) furcation defect using enamel matrix derivative (Emdogain®) following surgical debridement and conditioning of the root surface with PrefGel®.
Biological: Emdogain
Surgical treatment of a buccal Class II furcation defect was performed under local anesthesia. Following flap elevation, complete instrumentation of the root surfaces and furcation defect was performed using hand and powered instruments (scaling and root planing). Horizontal and vertical furcation involvement were measured. For PRF preparation, peripheral venous blood was collected into two vacuum tubes using a closed butterfly system. The tubes were centrifuged using a PRF DUO centrifuge. PRF from one tube was used to fill the furcation defect, while PRF from the second tube was compressed to form a membrane covering the furcation entrance. The flap was coronally positioned and secured with sling and interrupted interdental sutures using resorbable 6-0 sutures.
Also known as: PRF
Surgical treatment of a buccal Class II furcation defect was performed under local anesthesia. Following flap elevation, complete instrumentation of the root surfaces and furcation defect was performed using hand and powered instruments (scaling and root planing). Horizontal and vertical furcation involvement were measured. The exposed root surfaces were conditioned with 24% EDTA gel (PrefGel®, Straumann; pH 6.7) for 2 minutes, followed by thorough irrigation with sterile saline. Enamel matrix derivative (Emdogain®) was then immediately applied, starting from the most distant part of the furcation defect and covering the entire exposed root surface. The flap was coronally positioned and secured with sling and interrupted interdental sutures using resorbable 6-0 sutures.
Also known as: enamel matrix proteins
Change in Horizontal Furcation Probing Depth
Change in the horizontal probing depth of the furcation defect, measured at the furcation entrance before surgery and 6 months after surgery. The measurement was used to assess the horizontal component of furcation involvement and the clinical response to treatment.
Time frame: Baseline to 6 months after surgery
Change in Probing Pocket Depth
Change in periodontal probing depth at the treated furcation site, measured from m.gingivalis to the bottom of the pocket.
Time frame: Baseline to 6 months after surgery
Change in Clinical Attachment Level
Change in clinical attachment level at the treated furcation site, measured from cementoenamel junction to the bottom of the pocket.
Time frame: Baseline to 6 months after surgery
Change in Vertical Bone Loss
Change in vertical bone loss associated with the furcation defect, measured on three-dimensional imaging.
Time frame: Baseline to 6 months after surgery
Change in Horizontal Bone Loss.
Change in horizontal bone loss associated with the furcation defect, measured on three-dimensional imaging.
Time frame: Baseline to 6 months after surgery
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2021 to primary completion in May 2023, 17 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: P-prf
Medical University of Sofia